Company profile

Alex Gorsky
Incorporated in
Fiscal year end
Former names
Johnson & Johnson Et Al
IRS number

JNJ stock data

FINRA relative short interest over last month (20 trading days) ?


29 Apr 20
4 Jun 20
3 Jan 21


Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 20.69B 20.75B 20.73B 20.56B
Net income 5.8B 4.01B 1.75B 5.61B
Diluted EPS 2.17 1.5 0.66 2.08
Net profit margin 28.01% 19.33% 8.46% 27.27%
Net change in cash -1.78B 1.06B 1.87B -358M
Cash on hand 15.53B 17.31B 16.25B 14.38B
Cost of revenue 7.06B 7.13B 6.87B 6.94B
Annual (USD) Jan 17 Jan 16 Jan 12 Jan 11
Revenue 71.89B 70.07B 65.03B 61.59B
Net income 16.54B 15.41B 9.67B 13.33B
Diluted EPS 5.93 5.48 3.49 4.78
Net profit margin 23.01% 21.99% 14.87% 21.65%
Operating income 13.77B 17.7B
Net change in cash 5.24B 11.02B 416M
Cash on hand 18.97B 13.73B 2.71B 2.29B
Cost of revenue 21.79B 21.54B 20.36B 18.79B

Financial data from company earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
13 Mar 20 William D Perez Common Stock Buy Aquire P 127.686 500 63.84K 16,030
10 Mar 20 Washington A. Eugene Deferred Share Units Common Stock Grant Aquire A 0 368.271 0 22,014.304
10 Mar 20 Marillyn A Hewson Deferred Share Units Common Stock Grant Aquire A 0 226.948 0 1,447.948
10 Mar 20 Weinberger Mark A Deferred Share Units Common Stock Grant Aquire A 0 226.948 0 1,447.948
21 Feb 20 Thibaut Mongon Common Stock Sell Dispose S 147.96 39,224 5.8M 35,815.266
21 Feb 20 Thibaut Mongon Common Stock Option exercise Aquire M 90.44 19,224 1.74M 75,039.266
21 Feb 20 Thibaut Mongon Employee Stock Options Common Stock Option exercise Dispose M 90.44 19,224 1.74M 0
68.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2827 2914 -3.0%
Opened positions 107 353 -69.7%
Closed positions 194 107 +81.3%
Increased positions 1202 1112 +8.1%
Reduced positions 1284 1208 +6.3%
13F shares
Current Prev Q Change
Total value 2.32T 2.35T -1.6%
Total shares 1.79B 1.82B -1.5%
Total puts 13.59M 12.62M +7.7%
Total calls 15.87M 15.48M +2.5%
Total put/call ratio 0.9 0.8 +5.0%
Largest owners
Shares Value Change
Vanguard 233.82M $30.66B +2.4%
BLK BlackRock 192.55M $25.25B -0.2%
STT State Street 151.55M $19.87B -0.1%
Geode Capital Management 38.97M $5.1B +1.5%
State Farm Mutual Automobile Insurance 34.57M $4.53B 0.0%
NTRS Northern Trust 33.59M $4.4B -1.4%
BAC Bank of America 32.16M $4.22B -6.3%
BK Bank Of New York Mellon 31.8M $4.17B -3.2%
Wellington Management 30.56M $4.01B +10.8%
Massachusetts Financial Services 29.53M $3.87B +7.7%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -28.38M EXIT
Capital World Investors 21.2M +13.7M +182.9%
Fisher Asset Management 1.48M -10.61M -87.7%
Advisor 9.46M +9.46M NEW
Vanguard 233.82M +5.52M +2.4%
Clearbridge Advisors 6.69M -4.59M -40.7%
Arrowstreet Capital, Limited Partnership 7.07M +4.55M +180.9%
Boston Partners 6.48M +4.36M +205.8%
Charles Schwab Investment Management 16.57M +4.22M +34.2%
Charles Schwab Investment Advisory 0 -4.01M EXIT

Financial report summary

  • Global sales in the Company’s pharmaceutical and medical devices segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
  • The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
  • Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
  • Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
  • The Company may not be able to successfully secure and defend intellectual property rights essential to the Company’s businesses.
  • The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
  • Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
  • The Company faces increasing regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
  • The Company faces a variety of risks associated with conducting business internationally.
  • Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.
  • Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business.
  • An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation
Management Discussion
  • For discussion on results of operations and financial condition pertaining to the fiscal years 2018 and 2017 see the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2018, Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition.
  • In 2019, worldwide sales increased 0.6% to $82.1 billion as compared to an increase of 6.7% in 2018. These sales changes consisted of the following:
  • The net impact of acquisitions and divestitures on the worldwide sales growth was a negative impact of 1.7% in 2019 and a positive impact of 0.8% in 2018.
Content analysis ?
6th grade Avg
New words: Abtahi, actuarial, adjudication, Aizant, amp, appellate, Arizona, arsenic, attempt, authoritative, bench, bermekimab, Boehringer, broaden, caption, causally, chart, chromium, CLRA, CMF, combat, conferring, confidence, context, debtor, DECKER, Deleveraging, dermatological, detailed, developmental, diversified, doubtful, Draft, dropped, duration, earned, essential, evolving, expert, filled, footprint, forecasted, foresee, forum, GEOGRAPHIC, hexavalent, IA, Idaho, Inclusive, Ingelheim, installment, Jr, judge, Los, macroeconomic, magnitude, Mallincrodt, Marcan, Medacta, modified, mouthwash, NDMA, Nippon, objected, outbreak, pandemic, persistence, PLC, Polymorph, pre, Precision, preparing, presence, pretrial, prevent, profile, prolonged, PROPLAN, ranitidine, receipt, recovery, redaction, remote, replied, rescheduled, robust, Sanofi, science, scope, Shinyaku, shortly, situation, Skin, Specgx, speed, spread, standing, Stockholder, substitute, talcum, testimony, therapy, timeline, undistributed, uninterrupted, Unlimited, unpredictability, UNREGISTERED, unsafe, upper, Verb, Verily, vested, VGYAAN, Virtual, waiving, workforce, working, XBiotech, Xtant, Zantac
Removed: Abbvie, Acerta, acquire, ACUVUE, adequately, admitted, advance, Amerigen, applied, approximate, Argentum, ARIA, AstraZeneca, ATTUNE, authorizing, AVEENO, Beauty, benchmark, Bio, Brazil, CAFC, Cellex, certificate, Citron, CJEU, close, closure, commencement, COMPEED, CONSTA, DARZALEX, delisted, determining, disclosing, discount, disposal, DURAGESIC, English, ENSEAL, ERLEADA, exclusion, exclusively, Fortive, generated, Glenmark, granting, Hexal, Hikma, Hydrogel, IMBRUVICA, implicit, Index, INTELENCE, intervened, invalidating, INVOKANA, issuing, Job, jointly, JSI, JULUCA, KAPUSTA, lease, leasing, LEVAQUIN, license, licensed, LifeScan, long, Lonza, master, Mentor, minimum, MONOCRYL, negligible, negotiated, NEUTROGENA, NIZORAL, NUCYNTA, obligation, OIS, OLYSIO, OPSUMIT, original, Overnight, overturned, ownership, Par, Parliament, partial, PDS, permitted, Pharmaq, PHYSIOMESH, PINNACLE, pipeline, POS, procedure, processing, prospective, protective, Pvt, Qilu, Reclassification, reclassify, rehearing, relator, relaunch, RELIEVA, Rembrandt, rental, repurchase, retrospectively, returned, revoked, RoC, ROU, Searle, SEC, SELECT, separating, short, SOFR, source, space, SPC, STELARA, stranded, STRATAFIX, sublicensing, supplementary, suspended, SUSTENNA, Swap, SYMTUZA, Targeted, tender, term, terminate, threatened, Tokyo, Topic, TRACLEER, TREMFYA, UC, UK, unpatentable, upheld, UPTRAVI, Uvadex, VICRYL, whistleblower, Wockhardt, Women, XARELTO, Xts, ZYTIGA